WE ARE SOLDOUT

Days
Hrs
Mins
Secs

Blog

Opportunities Abound: China’s Evolving Vaccine Cooperation and Impact in Asia

01 June 2022

By

Wei Jian Cheng

Share

This article was originally featured here.

4 mins read

As the 75th World Health Assembly draws to a conclusion, one of the key messages in the area of global pandemic preparedness has been the need to diversify vaccine manufacturing across emerging economies. Cooperation in the development of vaccines has become all the more necessary as we consider the desire for global health security and sufficient vaccine supply for both pandemics and routine immunizations across all regions. Under this context it has been interesting to see how vaccine cooperation between China and the rest of Asia has evolved. 

Throughout 2021, China delivered vaccines through direct bilateral distribution, with almost two-thirds of a total of 1.58 billion doses of COVID-19 vaccines delivered to Asian countries, the most out of any continent. Gradually, China’s shifted its focus towards fill-to-finish projects and vaccine technology transfer, marking the start of more sustainable partnerships. This was implemented quickly within the region, an attribute to Asia’s growing desire and capacity for vaccine R&D and production. With China’s expanding cooperation within the region, it is crucial to understand how this could open doors to developing vaccine R&D around the region and beyond.

Figure 1: Monthly regional deliveries of Chinese COVID-19 Vaccines

Asia’s growing capacity for vaccine R&D and production

With the experience of the SARS outbreak back in 2003, Asia has been drawing investments into building healthcare and pharmaceutical infrastructures. Based on an analysis by The Economist in 2018, the expected growth CAGR in pharmaceutical spending by countries in Asia up to 2022 is projected to be 7.63%, much higher than the average of 4.81% across 2013 to 2017. The significant increase highlights Asia’s willingness to expand their pharmaceutical sector, thus presenting attractive opportunities for foreign companies to enter the region, whether that be through building vaccine manufacturing capacity in Southeast Asia, or dedicating resources for R&D and preparedness in East Asia. In some countries, this also reflects a desire to assume more regional leadership in global health, especially through collaborating with international organizations such as Gavi the Vaccine Alliance, COVAX, the International Vaccine Institute, GPEI (Global Polio Eradication Initiative), CEPI (Coalition for Epidemic Preparedness Innovations) and more.

Figure 2: Countries in Asia actual and projected average compound annual growth in pharmaceutical spending (US$)

Regional cooperation in vaccine R&D between China and Asia

Looking ahead to developing vaccine cooperation outside of vaccine deliveries, Chinese President Xi Jinping first proposed the six-point Global Vaccine Cooperation Action Initiative back in October 2021 during an address to the 16th G20 Leaders’ summit. He emphasized on strengthening vaccine R&D cooperation and support vaccine companies in conducting joint R&D and production. 

In response to this, multiple Chinese companies and institutions quickly formed significant partnerships with their Asian counterparts. The swift and effective collaboration helps to sustain a timely and improved accessibility to vaccines around the region and some of these collaborations are illustrated below. 

1. Bilateral cooperation in vaccine distribution 

While China has reduced the amount of vaccine distribution from the country, cooperation in vaccine distribution is crucial for helping Asia grow to achieve self-sustainability as a region for countries that may not have the proper infrastructure.

Country Collaborator Bilateral cooperation in vaccine distributions
Indonesia Sinovac / Bio Farma Licensed state-owned Bio Farma to produce CoronaVac and act as a production hub within the region, with anticipated production of 250 million doses per year.
Malaysia Sinovac / Pharmaniaga Berhad Licensed to be the main distributor for Omicron-specific vaccine within the region, hence increasing accessibility of vaccines for countries within Asia. 

2. Joint production and vaccine R&D partnerships

Joint productions and R&D partnerships are also becoming increasingly common as part of China’s shift to sustainable forms of vaccine cooperation.

Country Collaborator Joint Productions and Vaccine R&D Partnerships
Myanmar Sinopharm / Ministry of Industry Joint production of Sinopharm’s COVID-19 vaccines in Myanmar to enhance Myanmar’s vaccine production capacity and fulfill local vaccination demand.
Malaysia CanSino / Solution Biologics Joint production of CanSino with local company Solution Biologics to produce 3-6 million doses per month. 
Japan WestVac Biopharma / Nagasaki University Vaccine R&D partnership to conduct clinical trials and apply for Emergency Use Authorization (EUA) in Japan for WestVac’s recombinant COVID-19 (sf9) vaccine.

Some other private sector investments in R&D for further vaccine R&D in Asian countries are also worth mentioning, such as YishengBio’s acquisition of Singapore’s NewBiomed for the PIKA adjuvant technology. This propelled their R&D capabilities forward to utilize the novel technology and develop multiple vaccines such as the current PIKA recombinant COVID-19 vaccine.

Final thoughts

With the exponential growth of vaccine R&D in these countries, no doubt the region has significant potential to achieve and sustain vaccine self-sufficiency, providing further contributions towards the global healthcare agenda. Henceforth, the door is now wide open for countries to strengthen cooperation and lay hold of the opportunities that lie ahead, working towards a robust infrastructure and network for the current and future pandemics.

References

A. Environmental Stewardship
To protect the environment, we organize programmes like mangrove nursery and Reforestation, Coastal and River Clean-Up, Community Based Environmental Solid Waste Management, Environmental IEC Campaign and Eco-Academy

B. Food Security and Sustainable Livelihood
To ensure a sustainable livelihood for the community, eco-tourism include Buhatan River Cruise Visitor Center Buhatan River Mangrove Boardwalk are run by the community. Others include Organic Vegetable and Root crops Farming, Vegetable and Root crops Chips and by-products Processing and establishing a Zero waste store.

C. Empowered Communities
To empower the community, we provide product and Agri-Enterprise Development Training, Immersion and Learnings Exchange Program, Earth Warrior Training and Community Based Social Entrepreneurship Training

Author

Wei Jian Cheng

Research Analyst Intern at Bridge Consulting

Wei Jian is a Chemical Engineering graduate of the National University of Singapore and a Research Analyst Intern at Bridge Consulting. He has an avid interest in the pharmaceutical industry. Having a technical background, he is experienced in handling and visualizing data and has strong knowledge on global healthcare issues.

Did you enjoy reading this?

You might also be interested in

Webinars

AVPN Webinar: Impact Measurement & Management with a Gender Lens

Blog

Is there investment potential in Myanmar?

Blog

10 Opportunities to Build Resilience to Climate, COVID and Economic Crises in Asia

Sign up for the #1 newsletter on social investment in Asia.

This field is for validation purposes and should be left unchanged.

We see social investment as a continuum that encompasses everything from philanthropy and venture philanthropy to impact investing, CSR and sustainable investment. We call this the “Continuum of Capital”.

We see social investment as a continuum that encompasses everything from philanthropy and venture philanthropy to impact investing, CSR and sustainable investment. We call this the “Continuum of Capital”.

©2021 Asian Venture Philanthropy Network | AVPN is registered in Singapore as a charity (UEN 201016116M)

|

|